Get the Stockscreener App
2.775
9.90%
-0.305
Cvrx Inc stock is traded at $2.775, with a volume of 852.86K.
It is down -9.90% in the last 24 hours and down -43.48% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$3.08
Open:
$3.04
24h Volume:
852.86K
Relative Volume:
1.30
Market Cap:
$74.04M
Revenue:
$59.07M
Net Income/Loss:
$-52.66M
P/E Ratio:
-1.3806
EPS:
-2.01
Net Cash Flow:
$-40.16M
1W Performance:
+17.09%
1M Performance:
-43.48%
6M Performance:
-41.46%
1Y Performance:
-60.53%
1-Day Range:
$2.76
$3.08
1-Week Range:
$2.31
$3.24
52-Week Range:
$2.20
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
2.7791 | 82.06M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
110.09 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.01 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.64 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.53 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.77 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com India
Cantor cuts CVRx stock price target on sales execution challenges - Investing.com
Cantor Fitzgerald Issues Pessimistic Forecast for CVRx (NASDAQ:CVRX) Stock Price - MarketBeat
Johnson & Johnson Invests $20.69 Billion in CVRx, Inc. $CVRX - MarketBeat
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
CVRx, Inc. (CVRX) investor Jorey Chernett discloses 5.5% beneficial stake - Stock Titan
Cvrx COO Brent Binkowski sells $3,338 in company stock By Investing.com - Investing.com South Africa
Cvrx COO Brent Binkowski sells $3,338 in company stock - Investing.com
Cvrx COO Brent Binkowski buys $76,432 in company stock By Investing.com - Investing.com Australia
CVRx (NASDAQ:CVRX) COO Brent Binkowski Buys 26,223 Shares of Stock - MarketBeat
Cvrx COO Brent Binkowski buys $76,432 in company stock - Investing.com
CVRx (CVRX) COO Brent Binkowski purchases 26,223 shares in open-market buy - Stock Titan
Insider Purchase: CHIEF OPERATING OFFICER of $CVRX Buys 26,223 Shares - Moomoo
CVRx (CVRX) Q2 2026 Earnings Call Transcript - AOL.com
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages - GlobeNewswire
CVRx (CVRX) COO executes 1,309-share sell-to-cover under Rule 10b5-1 plan - Stock Titan
Block & Leviton investigates CVRx for possible securities law violations after revenue guidance cut. - Pluang
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches - MarketBeat
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
CVRx chief revenue officer exits amid slowing sales and execution concerns - The Business Journals
CVRx at Canaccord Genuity growth conference: reimbursement gains, sales strain - Investing.com UK
CVRx, Inc. $CVRX Shares Acquired by Royal Bank of Canada - MarketBeat
CVRx names interim sales head as revenue officer departs By Investing.com - Investing.com Australia
Form 8K CVRx Inc For: 11 August By Investing.com - Investing.com UK
CVRx to replace CRO after cutting guidance and DOJ civil inquiry - MassDevice
CVRx, Inc. Investors With Losses Should Contact Block & Leviton About Securities Fraud Investigation - The National Law Review
CVRx, Inc. (CVRX) Presents at Canaccord Genuity's 46th Annual Growth ConferenceSlideshow - Seeking Alpha
CVRX: Execution improvements and payer wins position the therapy for broader adoption and growth - TradingView
CVRx Inc (CVRX) Stock News Today - TradingKey
Craig-Hallum Downgrades CVRx Inc(CVRX.US) to Hold Rating - Moomoo
CVRx names interim sales head as revenue officer departs - Investing.com
CVRx Announces Sales Leadership Transition - The Manila Times
CV's Robert John departs as Chief Revenue Officer - TradingView
CVRx, Inc. Announces Executive Changes, Effective August 11, 2026 - marketscreener.com
CVRx Inc(CVRX) Stock Options Chain | Quotes & News - moomoo.com
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - WBOC TV
CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; ... - Caledonian Record
CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses - GlobeNewswire Inc.
(CVRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
CVRx, Inc. (NASDAQ:CVRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
CVRx Falls To US$2.39, But Insiders Sold At Lower Price - Moomoo
CVRx (NASDAQ:CVRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Law firm probes CVRx over possible securities l... - Pluang
CVRx Stock Is Falling Overnight: Here's What's Driving the Move - webull.com
CVRx (CVRX) Stock Reels From Guidance Cut And Cash Burn Fears - simplywall.st
CVRx, Inc. Stock 12‑Month Price Target Cut to $8, Implies 35% Upside - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com
CVRx cuts revenue forecast, faces DOJ probe and sales challenges, prompting investor lawsuit investigation - Pluang
CVRx, Inc. (CVRX) Investors Who Suffered Losses Are - GlobeNewswire
$CVRX stock is down 55% today. Here's what we see in our data. - Quiver Quantitative
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Binkowski Brent | CHIEF OPERATING OFFICER |
Aug 12 '26 |
Sale |
2.55 |
1,309 |
3,338 |
30,291 |
| Adamson Philip B. | Chief Medical Officer |
Mar 02 '26 |
Sale |
7.90 |
1,262 |
9,973 |
61,578 |
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):